Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients

Computational and Structural Biotechnology Journal

Volumn 13, Issue , 2015, Pages 153-158

  Göhring, Katharina ^a   Hamprecht, Klaus ^a   Jahn, Gerhard ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Antivirals; Cytomegalovirus; HCMV; Multidrug resistance; Stem cell transplantation

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CYTOMEGALOVIRUS INFECTION; GENE MUTATION; GENOTYPING TECHNIQUE; HIGH RISK POPULATION; HUMAN; MULTIDRUG RESISTANCE; OPEN READING FRAME; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STEM CELL TRANSPLANTATION; UL54 GENE; UL97 GENE; VIRUS GENE; VIRUS MUTATION;

EID: 84938681622     PISSN: None     EISSN: 20010370     Source Type: Journal    
DOI: 10.1016/j.csbj.2015.01.003     Document Type: Review

References (93)

1. C.N. Kotton CMV: prevention Diagn Ther Am J Transplant 13 2013 24
2. C. Gilbert, and G. Boivin Human cytomegalovirus resistance to antiviral drugs Antimicrob Agents Chemother 49 2005 873 883
3. F. Baldanti, N. Lurain, and G. Gerna Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs Hum Immunol 65 2004 403 409
4. T. Eckle, L. Prix, G. Jahn, T. Klingebiel, R. Hangretinger, B. Selle, and et al. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes Blood 96 2000 3286 3289
5. Limaye AP. Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients Semin Respir Infect 17 2002 265 273
6. M. Chevilotte, J. von Einem, B.M. Meier, F.M. Lin, H.A. Kestler, and T. Mertens A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotype Antiviral Res 85 2 2010 318 327
7. D.C. Quenelle, B. Lampert, D.J. Collins, T.L. Rice, G.R. Painter, and E.R. Kern Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies J Infect Dis 202 2010 1492 1499
8. T.E. Komatsu, A. Pikis, L.K. Naeger, and P.R. Harrington Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative pathways Antivir Res 101 2014 12 25
9. S. Stoelben, W. Arns, L. Renders, J. Hummel, A. Mühlfeld, M. Stangl, and et al. Pre-emptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study Transpl Int 27 2014 77 86
10. R.K. Avery, F.M. Marty, S. Strasfeld, I. Lee, A. Arrieta, S. Chou, and et al. Oral maribavir for treatment of resistant or refractory cytomegalovirus infections in transplant recipients Abstr V-1256. Abstr 49th intersci. conf. Antimicrobiol agents chemother San Francisco,CA 2009
11. F.M. Marty, P. Ljungman, G.A. Papanicolaou, D.J. Winston, R.F. Chemaly, L. Strasfeld, and et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double blind, placebo controlled, randomised trial Lancet Infect Dis 11 2011 284 292
12. D.J. Winston, F. Saliba, E. Blumberg, M. Abouljoud, J.B. Gracia-Diaz, J.A. Gross, and et al. Efficacy and safety of maribavir dose 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial Am J Transplant 12 2012 3021 3030
13. N.S. Lurain, and S. Chou Antiviral drug resistance of human cytomegalovirus J Clin Microbiol Rev 23 2010 689
14. V. DelĺOste, D. Gatti, F. Gugliesi, M. De Andrea, M. Bawadekar, I. Lo Cigno, and et al. Innate nuclear sensor IFI16 translocates into the cytoplasm during early stage on in vitro human cytomegalovirus infection and is entrapped in the egressing virions during late stage J Virol 88 2014 6970 6982
15. M. Boeckh, and P. Ljungman How I treat cytomegalovirus in hematopoietic cell transplant recipients Blood 113 2009 5711 5719
16. C.N. Kotton, D. Kumar, and A.M. Caliendo International consensus guidelines on the management of cytomegalovirus in solid organ transplantation Transplantation 89 2010 779 795
17. H.A. Myhre, D. Haug Dorenberg, K.I. Kristiansen, H. Rollag, T. Leivestad, A. Asber, and et al. Incidence and outcome of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients Transplantation 92 2011 217 223
18. A. Schreiber, G. Härter, A. Schuber, D. Bunjes, T. Mertens, and D. Michel Antiviral treatment of cytomegalovirus infection and resistant strains Expert Opin Pharmacother 10 2009 191 209
19. M. Hakki, and S. Chou The biology og cytomegalovirus drug resistance Curr Opin Infect Dis 24 2011 605 611
20. P. Lischka, and H. Zimmermann Antiviral strategies to combat cytomegalovirus infections in transplant recipients Curr Opin Pharmacol 8 2008 541
21. G. Andrei, C.E. De, and R. Snoeck Drug targets in cytomegalovirus infection Infect Disord Drug Targets 9 2009 162
22. A.J. Eid, S.K. Arthurs, P.J. Deziel, M.P. Wilhelm, and R.R. Razonable Emergence of drug resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes Clin Transplant 48 2008 162
23. R. Schuurman, L. Demeter, P. Reichelderfler, J. Tijnagel, T. De Groot, and C. Boucher Worldwide evaluation of DNA sequencing approach for identification of drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase J Clin Microbiol 37 1999 2291 2296
24. S. Margeridon-Thermet, N.S. Shulman, A. Ahmed, R. Shahari, T. Liu, C. Wang, and et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI-)-treated patients and NRTI-naïve patients J Infect Dis 199 2009 1275 1285
25. C. Wang, Y. Mitsuya, B. Gharizadeh, M. Ronaghi, and R.W. Shafer Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV1 drug resistance Genome Res 17 2007 1195 1201
26. K. Göhring, T. Feuchtinger, E. Mikeler, P. Lang, G. Jahn, R. Handgretinger, and et al. Dynamics of the emergence of a drug resistant human cytomegalovirus strain in a pediatric stem cell transplant recipient detected by a new real-time PCR approach J Mol Diagn 11 2009 364 368
27. G. Boivin, S. Chou, M.R. Quirk, A. Erice, and M.C. Jordan Detection of ganciclovir resistance mutations of cytomegalovirus (CMV) DNA in leucozytes of patients with fatal disseminated CMV diseases J Infect Dis 173 1996 523 528
28. G. Boivin, C. Gilbert, A. Gaudreau, I. Greenfield, R. Sudlow, and N.A. Roberts Rate of emergence of cytomegalovirus (CMV) mutations in leucocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis J Infect Dis 184 2001 1598 1602
29. S. Chou, A. Erice, M.C. Jordan, G.M. Vercellotti, K.R. Michels, C.L. Talarico, and et al. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance J Infect Dis 171 1995 576 583
30. S. Chou, S. Guentzel, K.R. Michels, R.C. Miner, and W.L. Drew Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates J Infect Dis 172 1995 239 242
31. A. Erice, J.L. Gil-Roda, L. Perez, H.H. Balfour, K.J. Sannerud, M.N. Hanson, and et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients J Infect Dis 175 1997 1087 1092
32. C. Gilbert, J. Handfiels, E. Toma, R. Lalonde, M.G. Bergeron, and G. Boivin Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients AIDS 12 1998 125 129
33. K. Göhring, E. Mikeler, G. Jahn, and K. Hamprecht Rapid simultaneous detection by real-time PCR of cytomegalovirus UL97 mutations in codons 460 and 520 conferring ganciclovir resistance J Clin Microbiol 44 2006 4541 4544
34. K. Göhring, E. Mikeler, G. Jahn, F. Rohde, and K. Hamprecht Rapid semiquantitative real-time PCR for the detection of human cytomegalovirus UL97 mutations conferring ganciclovir resistance Antivir Ther 13 2008 461 466
35. S. Chou Antiviral drug resistance in human cytomegalovirus Transpl Infect Dis 1 1999 105 114
36. M.L. Landry, S. Stanat, K. Biron, P. Brambilla, W. Britt, J. Jokela, and et al. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates Antimicrob Agents Chemother 44 2000 688 692
37. N.S. Lurain, S.M. Bhorade, K.J. Pursell, R.K. Avery, V.V. Yeldandi, C.M. Isada, and et al. Analysis and characterization of antiviral-drug-resistant cytomegalovirus isolates from solid organ transplant recipients J Infect Dis 186 2002 760 768
38. L. Prix, J. Maierl, G. Jahn, and K. Hamprecht A simplified assay for screening of drug resistance of cell-associated cytomegalovirus strains J Clin Virol 24 1998 29 37
39. M. Chevillotte, A. Schubert, T. Mertens, and J. von Einem Fluorescence-based assay for phenotypic characterization of human cytomegalovirus polymerase mutations regarding drug susceptibility and viral replicative fitness Antimicrob Agents Chemother 53 2009 3752 3761
40. V. Sullivan, C.L. Talarico, S.C. Stanat, M. Davis, D.M. Coen, and K.K. Biron A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cell Nature 358 1992 162 164
41. T. Cihlar, M.D. Fuller, and J.M. Cherrington Characterization of drug resistant associated mutations in human cytomegalovirus DNA polymerase gene by using recombinant mutant virus generated from overlapping DNA fragments J Virol 72 1998 5927 5936
42. S. Warming, S.N. Constantino, D.L. Court, N.A. Jenkins, and N.G. Copeland Simple and highly efficient BAC recombineering using galK selection Nucleic Acids Res 33 2005 e36
43. M. Martin, E. Gilbert, E. Covington, and G. Boivin Characterization of human citomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of bacterial artificial chromosom containing the HCMV genome J Infect Dis 194 2006 579 583
44. E.M. Borst, G. Hahn, U.H. Koszinowski, and M. Messerle Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants J Virol 73 1999 8320 8329
45. B.K. Tischer, J. von Einem, B. Kaufer, and N. Osterrieder Two-step mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli Biotechniques 40 2006 191 197
46. B.K. Tischer, G.A. Smith, and N. Osterrieder En passant mutagenesis: a two step markerless recombination system Methods Mol Biol 634 2010 421 430
47. T. Eckle, G. Jahn, and K. Hamprecht High impact of an expanded restriction fragment length polymorphism assay on detection of gancoclovir- resistant UL97 mutants of human cytomegalovirus Antimicrob Agents Chemother 47 1 2003 242 243
48. K. Göhring, D. Wolf, W. Bethge, Faul C. Mikeler, W. Vogel, and et al. Dynamics of coexisting HCMV UL97- and UL54 drug resistance assicoated mutations in patients after haematopoetic cell transplantation J Clin Virol 57 2013 43 49
49. J.M. Iwanesko, G.M. Scott, J.B. Ziegler, and W.D. Rawlinson Emergence and persistence of multiple antiviral-resistant CMV strains in a highly imunocompromised child J Clin Virol 40 2007 152 155
50. C. Sinzger, G. Hahn, M. Digel, R. Katona, K.L. Sampaio, M. Messerle, and et al. Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E J Gen Virol 89 2008 359 368
51. S. Chou Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance Antimicrob Agents Chemother 54 2010 2372 2378
52. B. Abraham, S. Lastere, J. Reynes, F. Bibollet-Ruche, N. Vidal, and M. Segondy Ganciclovir resistance and UL97 gene mutations in cytomegalovirus blood isolates from patients with AIDS treated with ganciclovir J Clin Virol 13 1999 141 148
53. D. Boutolleau, C. Deback, C. Bressollette-Bodin, S. Varnous, N. Dhedin, B. Barrou, and et al. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection Antiviral Res 81 2009 174 179
54. S. Chou, R.H. Waldemer, A.E. Senters, S. Michels, G.W. Kemble, R.C. Miner, and et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir J Infect Dis 185 2002 162 169
55. I.L. Smith, J.M. Cherrington, R.E. Jiles, M.D. Fuller, W.R. Freeman, and S.A. Spector High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes J Infect Dis 176 1997 69 77
56. D.G. Wolf, I.L. Smith, D.J. Lee, W.R. Freeman, M. Flores-Aguilar, and S.A. Spector Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma J Clin Invest 95 1995 257 263
57. S. Chou, L.C. Van Wechel, H.M. Lichy, and G.I. Marousek Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene Antimicrob Agents Chemother 49 2005 2710 2715
58. D.A. Jabs, B.K. Martin, M.S. Forman, J.P. Dunn, J.L. Davis, D.V. Weinberg, and et al. Longitudinal observations on mutations conferring ganciclovir resistance in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. The Cytomegalovirus and Viral Resistance Study Group Report Number 8 Am J Ophthalmol 132 2001 700 710
59. A.P. Limaye, L. Corey, D.M. Koelle, C.L. Davis, and M. Boeckh Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants Lancet 356 2000 645 649
60. J.E. Marfori, M.M. Exner, G.I. Marousek, S. Chou, and W.L. Drew Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients J Clin Virol 38 2007 120 125
61. M. Martin, N. Goyette, J. Ives, and G. Boivin Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis J Clin Virol 47 2010 321 324
62. M.N. Hanson, L.C. Preheim, S. Chou, C.L. Talarico, K.K. Biron, and et al. Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir Antimicrob Agents Chemother 39 1995 1204 1205
63. A.P. Limaye, G. Raghu, D.M. Koelle, J. Ferrenberg, M.L. Huang, and et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy J Infect Dis 185 2002 20 27
64. O. Ijichi, D. Michel, T. Mertens, K. Miyata, and Y. Eizuru GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97is partially reconstituted by a second mutation at D605E Antiviral Res 53 2002 135 142
65. C. Bourgeois, N. Sixt, J.B. Bour, and P. Pothier Value of a ligase chain reaction assay for detection of ganciclovir resistance-related mutation 594 in UL97 gene of human cytomegalovirus J Virol Methods 67 1997 167 175
66. F. Baldanti, E. Silini, A. Sarasini, L.C. Talarico, S.C. Stanat, and et al. A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate J Virol 69 1995 796 800
67. S. Chou, and L.C. Meichsner A nine-codon deletion mutation in the cytomegalovirus UL97 phosphotransferase gene confers resistance to ganciclovir Antimicrob Agents Chemother 44 2000 183 185
68. F. Baldanti, D. Michel, L. Simoncini, M. Heuschmid, A. Zimmermann, R. Minisini, and et al. Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system Antiviral Res 54 2002 59 67
69. R. Faizi Khan, S. Mori, Y. Eizuru, K. Kumura Ishii, and Y. Minamishima Genetic analysis of a ganciclovir-resistant human cytomegalovirus mutant Antiviral Res 40 1998 95 103
70. S. Hantz, D. Michel, A.M. Fillet, V. Guigonis, G. Champier, M.C. Mazeron, and et al. Early selection of a new UL97 mutant with a severe defect of ganciclovir phosphorylation after valaciclovir prophylaxis and short-term ganciclovir therapy in a renal transplant recipient Antimicrob Agents Chemother 49 2005 1580 1583
71. F. Baldanti, M.R. Underwood, C.L. Talarico, L. Simoncini, A. Sarasini, K.K. Biron, and et al. The Cys607Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients Antimicrob Agents Chemother 42 1998 444 446
72. L. Fischer, K. Laib-Sampaio, G. Jahn, K. Hamprecht, and K. Göhring Generation and characterisation of defined HCMV UL97- and UL54-mutants conferring drug resistance Antiviral Res 100 2013 575 577
73. L. Fischer, K. Laib-Sampaio, G. Jahn, K. Hamprecht, and K. Göhring Identification of newly detected, drug-related HCMV UL97- and UL54- mutations using a modified plaque reduction assay J Clin Virol 2015 [submitted for publication]
74. S. Chou, N.S. Lurain, K.D. Thompson, R.C. Miner, and W.L. Drew Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus J Infect Dis 188 2003 32 39
75. G.M. Scott, A. Weinberg, W.D. Rawlinson, and S. Chou Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates Antimicrob Agents Chemother 51 2007 89 94
76. S. Chou, G. Marousek, S. Guentzel, S.E. Follansbee, M.E. Poscher, J.P. Lalezari, and et al. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease J Infect Dis 176 1997 786 789
77. A. Ducancelle, G. Champier, S. Alain, F. Petit, M.J. Le Pors, and M.C. Mazeron A novel mutation in theUL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet Antivir Ther 11 2006 537 540
78. T. Cihlar, M.D. Fuller, A.S. Mulato, and J.M. Cherrington A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture Virology 248 1998 382 393
79. S. Chou, G. Marousek, S. Li, and A. Weinberg Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus J Clin Virol 43 2008 107 109
80. M. Mousavi-Jazi, L. Schloss, W.L. Drew, A. Linde, R.C. Miner, J. Harmenberg, and et al. Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity J Clin Virol 23 2001 1 15
81. K.L. Springer, S. Chou, S. Li, R.H. Giller, R. Quinones, J.E. Shira, and et al. How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients J Clin Microbiol 43 2005 208 213
82. F. Baldanti, M.R. Underwood, S.C. Stanat, K.K. Biron, S. Chou, A. Sarazini, and et al. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS J Virol 70 1996 1390 1395
83. A. Weinberg, D.A. Jabs, S. Chou, B.K. Martin, N.S. Lurain, M.S. Forman, and et al. Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis J Infect Dis 187 2003 777 784
84. M.Y. Shapira, I.B. Resnick, S. Chou, A.U. Neumann, N.S. Lurain, T. Stamminger, and et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation Clin Infect Dis 46 2008 1455 1457
85. S. Chou, G. Marousek, D.M. Parenti, S.M. Gordon, A.G. LaVoy, J.G. Ross, and et al. Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy J Infect Dis 178 1998 526 530
86. S. Chou, G.I. Marousek, L.C. Van Wechel, S. Li, and A. Weinberg Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens Antimicrob Agents Chemother 51 2007 4160 4162
87. S. Chou, R.C. Miner, and W.L. Drew A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance J Infect Dis 182 2000 1765 1768
88. V. Sullivan, K.K. Biron, C. Talarico, S.C. Stanat, M. Davis, L.M. Pozzi, and et al. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives Antimicrob Agents Chemother 37 1993 19 25
89. K. Hamprecht, T. Eckle, L. Prix, C. Faul, H. Einsele, and G. Jahn Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain J Infect Dis 187 1 2003 139 142
90. L. Prix, K. Hamprecht, B. Holzhüter, R. Handgretinger, T. Klingebiel, and G. Jahn A comprehensive restriction analysis of the UL97 region allows early detection of ganciclovir-resistant human cytomegalovirus in an immunocompromised child J Infect Dis 180 2 1999 491 495
91. M. Chevilotte, I. Ersing, T. Mertens, and J. von Einem Differentiation between polymorphism and resistance-associated mutations in human cytomegalovirus DNA polymerase Antimicrob Agents Chemother 54 2010 5004 5011
92. Y. Zhang, Z. Zhao, J. Sun, G. Cao, F. Zhao, J. Hu, and et al. A new mutation in the human cytomegalovirus UL97 gene may confer ganciclovir resistance in Chinese kidney transplant recipients Arch Virol 158 2013 247 250
93. S. Hantz, S. Cotin, E. Borst, A. Couvreux, A. Salmier, I. Garrigue, and et al. Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model Antiviral Res 98 2013 130 134